Table 2.

Performance of baseline anti-hbc level in predicting the os after TACE

Cut-off values	Sensitivity (%)	95% CI	Specificity (%)	95% CI	+LR	-LR
< 9.09	0	0.0-6.8	100	76.8-100.0		1
≤ 9.09	1.92	0.05-10.3	100	76.8-100.0		0.98
≤ 9.57	1.92	0.05-10.3	85.71	57.2-98.2	0.13	1.14
≤ 10.63	25	14.0-38.9	85.71	57.2-98.2	1.75	0.88
≤ 10.67	25	14.0-38.9	78.57	49.2-95.3	1.17	0.95
≤ 11.56	65.38	50.9-78.0	78.57	49.2-95.3	3.05	0.44
≤ 11.63	65.38	50.9-78.0	71.43	41.9-91.6	2.29	0.48
≤ 11.88*	90.38	79.0-96.8	71.43	41.9-91.6	3.16	0.13
≤ 11.98	90.38	79.0-96.8	64.29	35.1-87.2	2.53	0.15
≤ 12.04	92.31	81.5-97.9	64.29	35.1-87.2	2.58	0.12
≤ 12.06	92.31	81.5-97.9	57.14	28.9-82.3	2.15	0.13
≤ 12.15	96.15	86.8-99.5	57.14	28.9-82.3	2.24	0.067
≤ 12.57	96.15	86.8-99.5	42.86	17.7-71.1	1.68	0.09
≤ 12.7	98.08	89.7-100.0	42.86	17.7-71.1	1.72	0.045
≤ 13.77	98.08	89.7-100.0	0	0.0-23.2	0.98
≤ 14.99	100	93.2-100.0	0	0.0-23.2	1

^*The cut-off value has the highest sum of sensitivity and specificity;

OS Overall Survival, TACE transarterial chemoembolization, CI confidence Interval, +LR positive likelihood ratio, -LR negative likelihood ratio.